Arkolith/Insider Trading/JNCE/Form 4

Cole Hugh M

Chief Business OfficerJounce Therapeutics, Inc. (JNCE) · full profile →Form 4 · filed Jan 11, 2022
Net Selling
Open-Market Buys
$0
Open-Market Sells
$67K
Net Open-Market Flow
-$67K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 10, 2022Sell(S)6K$6.65$41K64K
Jan 7, 2022Sell(S)3K$7.30$25K70K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001640455-22-000008) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML